Literature DB >> 28823762

Placenta growth factor mediated gene regulation in sickle cell disease.

Vijay K Kalra1, Shuxiao Zhang2, Punam Malik3, Stanley M Tahara4.   

Abstract

Sickle cell anemia (SCA) is an autosomal recessive disorder caused by mutation in the β-globin gene. Pulmonary hypertension (PH), a complication of SCA, results in severe morbidity and mortality. PH is a multifactorial disease: systemic vasculopathy, pulmonary vasoconstriction, and endothelial dysfunction and remodeling. Placenta growth factor (PlGF), an angiogenic growth factor, elaborated from erythroid cells, has been shown to contribute to inflammation, pulmonary vasoconstriction and airway hyper-responsiveness (AH) in mouse models of sickle cell disease. In this review, we summarize the cell-signaling mechanism(s) by which PlGF regulates the expression of genes involved in inflammation, PH and AH in cell culture and corroborate these findings in mouse models of SCA and in individuals with SCA. The role of microRNAs (miRNAs) in the post-transcriptional regulation of these genes is presented and how these miRNAs located in their host genes are transcriptionally regulated. An understanding of the transcriptional regulation of these miRNAs provides a new therapeutic approach to ameliorate the clinical manifestations of SCA.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hypoxia-inducible factor; Placenta growth factor; Pulmonary hypertension; Sickle cell anemia; Transcriptional and post-transcriptional regulation; microRNAs

Mesh:

Substances:

Year:  2017        PMID: 28823762      PMCID: PMC5815962          DOI: 10.1016/j.blre.2017.08.008

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  95 in total

Review 1.  Pulmonary hypertension and nitric oxide depletion in sickle cell disease.

Authors:  H Franklin Bunn; David G Nathan; George J Dover; Robert P Hebbel; Orah S Platt; Wendell F Rosse; Russell E Ware
Journal:  Blood       Date:  2010-04-15       Impact factor: 22.113

Review 2.  Leukotrienes.

Authors:  Marc Peters-Golden; William R Henderson
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

3.  Increased levels of endothelin-1 in plasma of sickle cell anemia patients.

Authors:  A C Rybicki; L J Benjamin
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

4.  High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension.

Authors:  Nambirajan Sundaram; Anitaben Tailor; Laurel Mendelsohn; Janaka Wansapura; Xunde Wang; Tomoyasu Higashimoto; Michael W Pauciulo; William Gottliebson; Vijay K Kalra; William C Nichols; Gregory J Kato; Punam Malik
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

5.  Hypoxia-mediated expression of 5-lipoxygenase-activating protein involves HIF-1alpha and NF-kappaB and microRNAs 135a and 199a-5p.

Authors:  Caryn S Gonsalves; Vijay K Kalra
Journal:  J Immunol       Date:  2010-03-01       Impact factor: 5.422

Review 6.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

7.  Activated Transcription Factor 3 in Association with Histone Deacetylase 6 Negatively Regulates MicroRNA 199a2 Transcription by Chromatin Remodeling and Reduces Endothelin-1 Expression.

Authors:  Chen Li; Yu Zhou; Anastacia Loberg; Stanley M Tahara; Punam Malik; Vijay K Kalra
Journal:  Mol Cell Biol       Date:  2016-10-28       Impact factor: 4.272

8.  Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

Authors:  Kenneth I Ataga; Charity G Moore; Cheryl A Hillery; Susan Jones; Herbert C Whinna; Dell Strayhorn; Cathy Sohier; Alan Hinderliter; Leslie V Parise; Eugene P Orringer
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

Review 9.  Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders.

Authors:  Aernout Luttun; Marc Tjwa; Peter Carmeliet
Journal:  Ann N Y Acad Sci       Date:  2002-12       Impact factor: 5.691

10.  Placenta growth factor in sickle cell disease: association with hemolysis and inflammation.

Authors:  Julia E Brittain; Ben Hulkower; Susan K Jones; Dell Strayhorn; Laura De Castro; Marilyn J Telen; Eugene P Orringer; Alan Hinderliter; Kenneth I Ataga
Journal:  Blood       Date:  2009-12-29       Impact factor: 22.113

View more
  3 in total

1.  Interleukin-6 in pregnancy with sickle cell disease.

Authors:  Manuela Freire Hazin Costa; Leuridan Cavalcante Torres; Marina Cadena da Matta; Aderson da Silva Araújo; Ariani Impieri Souza
Journal:  Hematol Transfus Cell Ther       Date:  2019-05-11

Review 2.  The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease.

Authors:  Oluwabukola T Gbotosho; Maria G Kapetanaki; Gregory J Kato
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 7.561

3.  The molecular basis for the prothrombotic state in sickle cell disease.

Authors:  Arun S Shet; Maria A Lizarralde-Iragorri; Rakhi P Naik
Journal:  Haematologica       Date:  2020-10-01       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.